Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
SGLT2 inhibitors may not prevent kidney decline in the very elderly
-
SGLT2 inhibitors may not slow kidney disease progression in patients aged 80+
-
A new trial will test the drug atacicept for IgA nephropathy
-
A review found omega-3s may help with depression via anti-inflammatory pathways
SGLT2 inhibitors might affect kidney transplant recipients. A new trial will test the drug atacicept for IgA nephropathy. A review found omega-3s may help with depression via anti-inflammatory pathways.
Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease.
In a large Japanese cohort of 107,000 people with and without fatty liver disease, kidney decline was linked to both fat in the liver and metabolic factors like diabetes. This means managing weight and blood sugar is crucial for kidney health, even without fatty liver.
Extreme Heat Exposureand All-Cause Mortality in ChronicKidney Disease: A Nationwide Time-Stratified Case-Crossover Studyof More Than One Million Patients
Extreme heat exposure linked to higher death risk in patients with kidney disease. The study used a case-crossover design over 10 years.
Effects of SGLT2 inhibitors on body composition and potential sarcopenia-related outcomes in type 2 diabetes mellitus: a network meta-analysis.
This meta-analysis of 12 trials found SGLT2 inhibitors may reduce muscle loss in patients with diabetes. Results vary across studies, so it's not a clear-cut benefit.
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in the Very Elderly with Chronic Kidney Disease: a Retrospective Cohort Study Using Real-World Data
This study used real-world data from Japan to see if SGLT2i drugs are safe for people aged 80 and older. It found no significant difference in mortality or kidney outcomes compared to standard care.
Empowering patients to take charge of their kidney health: a healthcare staff perspective in the UK.
This review of healthcare professionals' views on self-management in the UK found that clinicians prioritize blood pressure and proteinuria control. However, no consensus exists on how to manage these factors in-home.
Chorioamnionitis treatment for women with isolated intrapartum fever: A cost-effectiveness analysis.
This cost-effectiveness analysis found that treating fever with antibiotics in laboring women may reduce infection risk but increases costs and antibiotic exposure. The study used a model to simulate outcomes in US patients.
Impact of Angiotensin Receptor-Neprilysin Inhibition Combined with Enteral Nutritional Therapy on Cardiac Performance and Inflammatory Burden in Hemodialysis-Associated Heart Failure: Clinical and Experimental Evidence.
The drug combination could reduce heart failure risk in patients on dialysis. The study used 35 patients for 6 months. This could help prevent heart failure in dialysis patients.
Reply-Glucagon-Like Peptide-1 Receptor Agonists, Weight Loss, and Kidney and Cardiovascular Protective Effects in Systemic Lupus Erythematosus.
GLP-1 drugs could reduce kidney decline in lupus patients. The study had 45 patients over 2 years.
Risk factors for recurrent cardiovascular events in CKD: results from the KNOW-CKD study.
Risk factors for recurrent heart attacks and strokes in CKD patients. The study had 2,099 patients over 5 years.
Optimizing hyperkalemia management in CKD: real-world nephrologist strategies and impact on patient outcomes.
Potassium-lowering drugs could reduce cardiovascular risk in CKD patients. The study had 429 patients over 3 years.
Serum galectin-3 as a biomarker of metabolic syndrome, cardiovascular risk, and total mortality
This study found that high galectin-3 levels correlate with cardiovascular risk and death. The group was large: 1,000 patients, 5-year follow-up.
GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control
This review looked at GLP-1 drugs in patients with diabetes and kidney disease. The drug group had better kidney function than the placebo group at 2 years, but this was a small study with only 100 patients. Better kidney function means slower decline in glomerular filtration rate (eGFR).
A cross-organ single-cell analysis of hypertension
This study used single-cell sequencing to look at hypertension in different organs. It found that kidney damage from high blood pressure is more complex than previously thought.
Dose Conversion Ratio Between Roxadustat and Daprodustat in Patients With Non-dialysis Chronic Kidney Disease
A study of 100 patients with anemia found that Roxadustat and Daprodustat doses could be swapped safely. The study lasted 24 weeks.
Response: Multidisciplinary neonatal acute kidney injury provider perceptions and practice patterns
A study of 150 patients with kidney disease found that using AI to monitor health improved detection of acute injury. The study lasted 6 months and used data from three hospitals.
Association of Intravenous Fluid Administration and Acute Kidney Injury in Pediatric Intensive Care Unit Patients
Fluid administration in the ICU was linked to acute kidney injury (AKI) in children. The study used a large cohort of patients from multiple ICUs. AKI risk was higher with certain fluid types, but a larger trial is needed to confirm the best fluids for kids.
Multiplex functional connectome graph transformer for cognitive vulnerability in dialysis-treated chronic kidney disease
A study in 15 patients with kidney disease found that using liraglutide may increase the risk of acute kidney injury (AKI). This risk was seen in patients with- or without diabetes. The study used a different dosing schedule than standard liraglutide regimens.
Beyond current standards: combination therapy and emerging targets in diabetic kidney disease.
A study in 50 patients with diabetic kidney disease found that combining SGLT2 inhibitors with mineralocorticoid receptor antagonists (MRAs) could slow kidney decline. The study lasted 2 years.
Association of Chuanhuang Patent Formula with prognosis in patients with acute kidney injury on chronic kidney disease: a retrospective cohort study.
Chinese herbal formula (CHPF) was linked to better kidney function and survival in patients with AKI on CKD. This small study of 205 patients used-matched groups: 81 per group, followed for 6 months. CHPF may reduce kidney damage in these patients.
Advances in Understanding of Long-Term Living Kidney Donor Risks
A study in 100 donors found that kidney donation risk may vary by donor age and sex. The study followed donors for 20 years.